A Randomized Phase 3 Study Comparing Pemetrexed-Carboplatin With Docetaxel-Carboplatin as First-Line Treatment for Patients With Locally Advanced or Metastatic Non-Small Cell Lung Cancer
A Randomized Phase 3 Study Comparing Pemetrexed-Carboplatin With Docetaxel-Carboplatin as First-Line Treatment for Patients With Locally Advanced or Metastatic Non-Small Cell Lung Cancer
The purpose of this study is to compare the combination of pemetrexed and carboplatin with the combination of docetaxel and carboplatin in terms of survival without Grade 3 or 4 toxicity in previously untreated patients with locally advanced or metastatic non-small cell lung cancer (NSCLC).
Inclusion Criteria:
Exclusion Criteria:
Ballarat, Victoria 3350, Australia
Frankston, Victoria 3199, Australia
Wendouree, Victoria 3355, Australia
Bunbury, Western Australia 6230, Australia
Barretos, 14784700, Brazil
Goiânia, 74075040, Brazil
Santo André, 09060-020, Brazil
São Paulo, 01224 010, Brazil
Beijing, 100036, China
Nanjing, 210002, China
Shanghai, 200032, China
Ciudad Obregón, 85100, Mexico
Durango, 34208, Mexico
Mexicali, 21000, Mexico
Mexico City, 11640, Mexico
Seoul, 120-752, South Korea
Suwon, 442-723, South Korea
Ulsan, 682-714, South Korea
Taichung, 404, Taiwan